EGFR-IN-192 

EGFR-IN-192 is an anticancer agent. EGFR-IN-192 inhibits EGFR (IC₅₀: 0.12 μM), downregulates the HIF-VEGF and PI3K/AKT/mTOR pathways, upregulates the tumor suppressor gene PTEN, and induces cell cycle arrest and apoptosis in tumor cells. EGFR-IN-192 exhibits antitumor activity and can be used in tumor research^[1].

EGFR-IN-192 (Compound 7) potently inhibits the proliferation of PC-3, HePG-2 and MCF-7 cancer cells with IC₅₀ values of 15.54 μM, 8.22 μM and 5.53 μM, respectively, and exhibits selectivity towards cancer cells compared to normal WI-38 fibroblasts^[1].
EGFR-IN-192 (48 h) induces G₂/M cell cycle arrest and apoptosis in MCF-7 cells^[1].
EGFR-IN-192 (5.53 μM; 48 h) downregulates the gene expressions of HIF-1α and VEGF in MCF-7 cells^[1].
EGFR-IN-192 (48 h) regulates the PI3K/AKT/mTOR pathway in MCF-7 cells by downregulating PI3K, AKT and mTOR, and upregulating PTEN^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

528.56

C₃₁H₂₄N₆O₃

O=C(N1)C(O)=C(NC(CN2)=NC3=C2C=CC=C3)C(C1=N4)=C(C5=CC=C(N(C)C)C=C5)C6=C4C7=CC=CC=C7C6=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. El-Hema HS, et al. Expanding the chemical and therapeutic landscape of 5H-Indeno[1,2-b]pyridin-5-one derivatives: Novel anticancer activity, EGFR inhibition, and modulation of HIF-VEGF and PI3K/AKT/mTOR pathways supported by computational insights. Bioorg Chem. 2026;170:109476.  [Content Brief]